[Statin therapy and muscle disorders].
Abel
Tatjána
T
Allami Egészségügyi Központ Szakrendelo Intézet Budapest. drabelt@t-online.hu
Fehér
János
J
D000069059:Atorvastatin; D001682:Biological Availability; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects / Q000378:metabolism; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects; D005464:Fluorobenzenes / Q000009:adverse effects; D000077340:Fluvastatin; D006207:Half-Life; D006538:Heptanoic Acids / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D007211:Indoles / Q000009:adverse effects; D008148:Lovastatin / Q000009:adverse effects; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D009135:Muscular Diseases / Q000139:chemically induced* / Q000378:metabolism; D017035:Pravastatin / Q000009:adverse effects; D011743:Pyrimidines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000378:metabolism; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects
D005229:Fatty Acids, Monounsaturated; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000077340:Fluvastatin; D000068718:Rosuvastatin Calcium; D003577:Cytochrome P-450 Enzyme System; D008148:Lovastatin; D000069059:Atorvastatin; D019821:Simvastatin; D017035:Pravastatin